Best biotech stocks
Updated November 16, 2026
We cover 149 US-listed biotech companies. The largest is Amgen Inc. (AMGN), worth $251.9B. These are the 20 with the highest analysis scores today.
| # | Company | Market cap | Upside to fair value | Dividend | Score |
|---|---|---|---|---|---|
| 1 | Exelixis, Inc.EXEL | $16.8B | +14% | — | 4.4 |
| 2 | Halozyme Therapeutics, Inc.HALO | $11.4B | +199% | — | 3.4 |
| 3 | Neurocrine Biosciences Inc.NBIX | $16.9B | +53% | — | 3.0 |
| 4 | Gilead Sciences, Inc.GILD | $208.5B | -35% | 1.9% | 2.8 |
| 5 | Adma Biologics, Inc.ADMA | $3.0B | -33% | — | 2.8 |
| 6 | BIO-TECHNE CorpTECH | $11.4B | -60% | 0.4% | 2.6 |
| 7 | Amgen Inc.AMGN | $251.9B | -26% | 2.2% | 2.4 |
| 8 | Argenx SEARGX | $59.6B | -72% | — | 2.4 |
| 9 | Vericel CorpVCEL | $2.9B | -66% | — | 2.4 |
| 10 | Qiagen NVQGEN | $10.3B | -37% | 0.7% | 2.0 |
| 11 | Krystal Biotech, Inc.KRYS | $9.0B | +30% | — | 2.0 |
| 12 | Biogen Inc.BIIB | $37.5B | -33% | — | 1.8 |
| 13 | Repligen Corp.RGEN | $10.7B | -76% | — | 1.8 |
| 14 | Tarsus Pharmaceuticals, Inc.TARS | $4.0B | -66% | — | 1.6 |
| 15 | Twist Bioscience CorpTWST | $7.4B | -98% | — | 1.4 |
| 16 | Adaptive Biotechnologies CorpADPT | $4.7B | -96% | — | 1.4 |
| 17 | Beam Therapeutics Inc.BEAM | $2.4B | — | — | 1.4 |
| 18 | BioNTech SEBNTX | $21.5B | -94% | — | 1.2 |
| 19 | ImmunityBio, Inc.IBRX | $6.4B | — | — | 1.2 |
| 20 | Relay Therapeutics, Inc.RLAY | $4.0B | — | — | 1.2 |
A closer look at the top three
Exelixis, Inc. (EXEL): It has revenue growth of 13% a year over three years, an average net margin of 23%, a P/E of about 21, an intrinsic value about 14% above the current price and an overall score of 4.4 out of 5 (strong company).
Halozyme Therapeutics, Inc. (HALO): It has revenue growth of 28% a year over three years, an average net margin of 33%, a P/E of about 25, an intrinsic value about 199% above the current price and an overall score of 3.4 out of 5 (good, with some weak spots).
Neurocrine Biosciences Inc. (NBIX): It has revenue growth of 24% a year over three years, an average net margin of 15%, a P/E of about 25, an intrinsic value about 53% above the current price and an overall score of 3.0 out of 5 (good, with some weak spots).
Frequently asked questions
What is the best biotech stock right now?
By today’s analysis score, Exelixis, Inc. (EXEL) ranks first with 4.4 out of 5. A score is one measure and does not replace a full analysis.
How many biotech stocks are listed in the US?
Our data covers 149 biotech companies, each with its own analysis page.
How is the 0–5 score calculated?
Each stock faces five numeric tests in each of five areas (value, future, past, financial health and shareholder returns); the overall score is the average of the five.
More lists and tools
Lists are generated automatically from SEC filings and market prices and rebuilt every day. They are a starting point for research, not a recommendation to buy or sell.